• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Ascensia Launches World’s First One-Year CGM System, Eversense® 365

by Jasmine Pennic 10/02/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Ascensia Diabetes Care has announced the U.S. launch of the Eversense® 365 continuous glucose monitoring (CGM) system, an advancement in diabetes management. 

– Developed by Senseonics Holdings, Inc., Eversense 365 is the world’s first and only CGM system to offer an entire year of continuous glucose monitoring with a single sensor. This innovative technology received FDA clearance last month for individuals with type 1 and type 2 diabetes aged 18 years and older.

Addressing the Challenges of Traditional CGMs

Eversense 365 tackles common frustrations associated with traditional CGMs, which typically require replacement every 10-14 days. Ascensia’s new commercial launch campaign highlights these challenges and how Eversense provides solutions:

  • Longevity: Unlike shorter-term CGMs that often fail prematurely, Eversense 365 lasts for a full year, minimizing disruptions and providing long-term peace of mind.
  • Durability: The system features a removable smart transmitter that can be easily reattached if accidentally knocked off, preventing device waste.
  • Accuracy: Eversense 365 offers exceptional accuracy with minimal false alerts, even during sleep, enabling confident diabetes management decisions.
  • Comfort: The sensor is implanted under the skin, and the gentle, silicone-based adhesives for the transmitter are changed daily, minimizing skin irritation and discomfort.

Improved Diabetes Management and Quality of Life

Studies have shown that Eversense can reduce diabetes distress and significantly improve glucose control. By minimizing the burden of CGM management, Eversense 365 empowers individuals to take control of their diabetes and enhance their quality of life.

Access and Affordability

Eversense 365 is widely covered by commercial insurance in the U.S., and Ascensia is actively working to expand access. The company is introducing the Eversense 365 Payment Assistance and Simple Savings (PASS) program to further enhance affordability. This program allows eligible individuals to pay as little as $199 out-of-pocket for a full year of continuous glucose monitoring with a single annual payment.

Availability

To learn more about Eversense 365, potential users can visit www.eversensecgm.com. Healthcare professionals interested in offering the system can sign up at www.ascensiadiabetes.com/eversense/become-a-provider/ or contact 844-SENSE4U (736-7348).

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Continuous Glucose Monitoring (CGM), Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |